Meeting
2022 ASCO Annual Meeting
Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.
Authors
Zhaohui Jin
University of Iowa, Iowa City, IA
Zhaohui Jin , Jesse G. Dixon , Joleen M. Hubbard , Cathy Eng , Christopher Hanyoung Lieu , Jean-Yves Douillard , Richard Adams , Timothy S. Maughan , Eric Van Cutsem , Alan P. Venook , Heinz-Josef Lenz , Volker Heinemann , Sebastian Stintzing , Richard S. Kaplan , Carsten Bokemeyer , Benoist Chibaudel , John Raymond Zalcberg , Takayuki Yoshino , Aimery De Gramont , Qian Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3572)
DOI
10.1200/JCO.2022.40.16_suppl.3572
Abstract #
3572
Poster Bd #
366
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.
First Author: B. Chibaudel
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Efficacy of bevacizumab-based treatment in early-onset treatment-naïve metastatic colorectal cancer patients: An ARCAD database analysis.
First Author: Zhaohui Jin
Poster
2021 ASCO Quality Care Symposium
Variable implementation of optimal therapeutic strategies in metastatic colorectal cancer: Reviewing rates of liver resection and triplet chemotherapy across Australian hospitals as potential quality indicators.
First Author: Catherine Dunn
Poster
2021 Gastrointestinal Cancers Symposium
Tumor bulk as a prognostic biomarker and predictor of benefit from anti-EGFR therapy in patients with metastatic colorectal cancer: Analysis of 476 patients from the ARCAD Clinical Trials Program.
First Author: Benjamin Adam Weinberg